ACROBiosystems manufactures recombinant proteins.
Business Model:
Revenue: $59M
Employees: 201-500
Address: 1 Innovation Way
City: Newark
State: DE
Zip: 19711
Country: US
ACROBiosystems develops recombinant antigens for emergency SARS-CoV-2 variants. They also produce a series of GMP-grade cytokines under the GMP-quality management system. Their products include fc receptor proteins, immune checkpoint proteins, llama IgG fc fusion proteins, biomarkers, CD antigens, and more.
Contact Phone:
+18008100816
Contact Email:
Listed Exchange:
Shenzhen Stock Exchange
Ticker Symbol:
301080
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2021 | IPO | - | 4/2017 | Venture Round | 1 | - |
Neovision Capital Neovision Capital |
10/2021 | IPO | - | 4/2017 | Venture Round | 1 | - |
Neovision Capital Neovision Capital |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|